Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ICLR
ICLR logo

ICLR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy ICON PLC (ICLR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
118.190
1 Day change
2.26%
52 Week Range
211.000
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

ICON PLC (ICLR) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock is trading at a multi-decade low valuation and analysts see potential upside, the company's financial performance is weak, and there are unresolved accounting issues that introduce significant risk. The lack of recent positive trading signals and the absence of strong catalysts further support a hold recommendation.

Technical Analysis

The MACD is positively expanding, suggesting bullish momentum, but the RSI is neutral at 73.283, indicating no clear overbought or oversold condition. The stock is trading near its resistance level (R1: 116.69), with converging moving averages, signaling indecision in the market.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The high put-call volume ratio (2.91) indicates bearish sentiment in the options market, with significantly more put volume than call volume.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
7

Positive Catalysts

  • Several analysts have upgraded the stock recently, citing its attractive valuation and the belief that the selloff related to accounting issues is overdone. The stock is trading at a multi-decade low valuation, which could present a long-term opportunity.

Neutral/Negative Catalysts

  • was extremely weak, with a 98.81% drop in net income and a 98.73% drop in EPS. Additionally, there is no recent news or significant trading activity from insiders or hedge funds to support a bullish case.

Financial Performance

In 2025/Q3, revenue increased slightly by 0.63% YoY to $2.04 billion, but net income dropped sharply by 98.81% YoY to $2.36 million. EPS also fell by 98.73% YoY to $0.03, and gross margin declined to 22.32%, down 9.08% YoY. These figures indicate significant financial struggles.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst ratings are mixed. While some analysts (e.g., BMO Capital, Jefferies) have upgraded the stock to Buy or Outperform due to its low valuation, others (e.g., Barclays, Citi, Rothschild & Co Redburn) have downgraded it due to accounting uncertainties and reduced price targets. The consensus price targets range from $75 to $135, with an average around $120, suggesting limited upside from the current price of $115.46.

Wall Street analysts forecast ICLR stock price to rise
13 Analyst Rating
Wall Street analysts forecast ICLR stock price to rise
6 Buy
7 Hold
0 Sell
Moderate Buy
Current: 115.580
sliders
Low
172
Averages
202.67
High
222
Current: 115.580
sliders
Low
172
Averages
202.67
High
222
BMO Capital
Sean Dodge
Market Perform
to
Outperform
upgrade
$100 -> $130
AI Analysis
2026-03-26
Reason
BMO Capital
Sean Dodge
Price Target
$100 -> $130
AI Analysis
2026-03-26
upgrade
Market Perform
to
Outperform
Reason
BMO Capital analyst Sean Dodge upgraded Icon to Outperform from Market Perform with a price target of $130, up from $100. The firm's recent analysis indicates continued improvements in Icon's large pharma backdrop. In additions, the shares are trading at a multi-decade low valuation, the analyst tells investors in a research note. BMO believes current share levels overly discount the risks from Icon's accounting review and longer-term AI fears overhanging the space. It sees current levels as an attractive entry point.
Citi
Patrick Donnelly
Neutral
downgrade
$200 -> $120
2026-03-11
Reason
Citi
Patrick Donnelly
Price Target
$200 -> $120
2026-03-11
downgrade
Neutral
Reason
Citi analyst Patrick Donnelly lowered the firm's price target on Icon to $120 from $200 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group post the Q4 reports. Citi sees room for upside to the Q1 outlooks if biopharma activity continues to improve. The firm named Agilent its top tools pick, Natera its top diagnostics pick, and Charles River its top contract research organization pick.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ICLR
Unlock Now

People Also Watch